Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment
- PMID: 28246893
- DOI: 10.1007/s00391-017-1199-1
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment
Abstract
The treatment of gout is based on several principles. Symptom control and termination of the inflammatory process are important early goals, whereas the urate level should be lowered in the long term to prevent further gout attacks and complications. The non-pharmacological approach is based on individually informing the patient on dietary measures and changes of life style. Besides physical measures, such as cold applications on the affected joint, various medications are available for treatment of an acute gout attack. The choice of drug depends on the individual risk profile. If non-steroidal anti-inflammatory drugs (NSAID) and coxibs are chosen it should be taken into account that the use is restricted in patients with renal insufficiency. Moreover, these drugs may have gastrointestinal side effects and are associated with increased cardiovascular morbidity and mortality. Colchicine has gastrointestinal side effects at high dosages but can also be used for differential diagnostics if there is a quick response to treatment. Steroids are an effective alternative and can be given orally or parenterally in patients with dysphagia. Moreover, steroids can be used in cases of renal insufficiency. After symptoms of the acute attack have subsided, urate lowering therapy should be initiated to prevent further attacks. Low-dose urate lowering therapy can be started during an acute gout attack when acute therapy is initiated. Allopurinol is still the medication of choice but its use is restricted in patients with renal insufficiency. A rare but serious side effect is allopurinol hypersensitivity syndrome. Febuxostat can be an alternative in patients who do not tolerate allopurinol. In February 2016, lesinurad, an URAT-1 and OAT-4 inhibitor, was approved in combination with allopurinol or febuxostat. Data on the effectiveness and safety of synthetic uricases and biologicals are still sparse for elderly patients. These substances are reserved for severe cases of gout.
Keywords: Acute gout flare; Colchicine prophylaxis; Geriatric patients; Parkinson disease; Urate-lowering therapy.
Similar articles
-
Does starting allopurinol prolong acute treated gout? A randomized clinical trial.J Clin Rheumatol. 2015 Apr;21(3):120-5. doi: 10.1097/RHU.0000000000000235. J Clin Rheumatol. 2015. PMID: 25807090 Clinical Trial.
-
Adherence and persistence to urate-lowering therapies in the Irish setting.Clin Rheumatol. 2016 Mar;35(3):715-21. doi: 10.1007/s10067-014-2823-8. Epub 2014 Nov 20. Clin Rheumatol. 2016. PMID: 25409858
-
Management of acute and chronic gouty arthritis: present state-of-the-art.Drugs. 2004;64(21):2399-416. doi: 10.2165/00003495-200464210-00003. Drugs. 2004. PMID: 15481999 Review.
-
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics.Z Gerontol Geriatr. 2018 Jul;51(5):579-584. doi: 10.1007/s00391-017-1198-2. Epub 2017 Feb 23. Z Gerontol Geriatr. 2018. PMID: 28233118 Review. English.
-
[Therapy of gout in 2024].Ther Umsch. 2024 Sep;81(5):160-163. doi: 10.23785/TU.2024.05.004. Ther Umsch. 2024. PMID: 39508813 Review. German.
Cited by
-
[Correlations of echocardiographic parameters in Gout patients: a retrospective analysis].Nan Fang Yi Ke Da Xue Xue Bao. 2020 May 30;40(5):752-758. doi: 10.12122/j.issn.1673-4254.2020.05.23. Nan Fang Yi Ke Da Xue Xue Bao. 2020. PMID: 32897200 Free PMC article. Chinese.
-
A brief review on in vivo models for Gouty Arthritis.Metabol Open. 2021 Jun 14;11:100100. doi: 10.1016/j.metop.2021.100100. eCollection 2021 Sep. Metabol Open. 2021. PMID: 34189452 Free PMC article. Review.
-
Suppressive Effect of Huzhentongfeng on Experimental Gouty Arthritis: An In Vivo and In Vitro Study.Evid Based Complement Alternat Med. 2019 Dec 4;2019:2969364. doi: 10.1155/2019/2969364. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31871475 Free PMC article.
-
The risk of nonalcoholic fatty liver disease in gout patients with frequent flares: a retrospective cohort study.Clin Rheumatol. 2023 May;42(5):1389-1395. doi: 10.1007/s10067-023-06510-1. Epub 2023 Jan 20. Clin Rheumatol. 2023. PMID: 36662337
-
Anti-Gouty Arthritis and Anti-Hyperuricemia Properties of Sanghuangporus vaninii and Inonotus hispidus in Rodent Models.Nutrients. 2022 Oct 21;14(20):4421. doi: 10.3390/nu14204421. Nutrients. 2022. PMID: 36297105 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical